Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F James

Showing results (961-970 of 1,011) with videos related to

Pageof 102
Sort By:
Blood|September 20, 2017
Ibrutinib for chronic graft-versus-host disease after failure of prior therapyDavid Miklos, Corey S Cutler, Mukta Arora, et al.
British Journal of Haematology|June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trialsJeffrey Jones, Anthony Mato, Steven Coutre, et al.
Blood|February 14, 2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceSusan O'Brien, Richard R Furman, Steven Coutre, et al.
Stem Cell Reports|July 4, 2020
A Highly Phenotyped Open Access Repository of Alpha-1 Antitrypsin Deficiency Pluripotent Stem CellsJoseph E Kaserman, Killian Hurley, Mark Dodge, et al.
Blood|February 21, 2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Neurosurgery|December 3, 2020
Low-Dose Intravenous Heparin Infusion After Aneurysmal Subarachnoid Hemorrhage is Associated With Decreased Risk of Delayed Neurological Deficit and Cerebral InfarctionMatthew J Kole, Aaron P Wessell, Beatrice Ugiliweneza, et al.
British Journal of Haematology|April 12, 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinibJeffrey A Jones, Peter Hillmen, Steven Coutre, et al.
Environmental Toxicology and Chemistry|September 18, 2007
Intra- and interlaboratory variability in acute toxicity tests with glochidia and juveniles of freshwater mussels (Unionidae)Ning Wang, Tom Augspurger, M Chris Barnhart, et al.
The Journal of Biological Chemistry|November 24, 1999
Engineering a glucose-responsive human insulin-secreting cell line from islets of Langerhans isolated from a patient with persistent hyperinsulinemic hypoglycemia of infancyW M MacFarlane, J C Chapman, R M Shepherd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSteven E Coutré, Richard R Furman, Ian W Flinn, et al.
Pageof 102

Showing results (961-970 of 1,011) with videos related to

Sort By:
Pageof 102
Blood|September 20, 2017
Ibrutinib for chronic graft-versus-host disease after failure of prior therapyDavid Miklos, Corey S Cutler, Mukta Arora, et al.
British Journal of Haematology|June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trialsJeffrey Jones, Anthony Mato, Steven Coutre, et al.
Blood|February 14, 2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceSusan O'Brien, Richard R Furman, Steven Coutre, et al.
Stem Cell Reports|July 4, 2020
A Highly Phenotyped Open Access Repository of Alpha-1 Antitrypsin Deficiency Pluripotent Stem CellsJoseph E Kaserman, Killian Hurley, Mark Dodge, et al.
Blood|February 21, 2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Neurosurgery|December 3, 2020
Low-Dose Intravenous Heparin Infusion After Aneurysmal Subarachnoid Hemorrhage is Associated With Decreased Risk of Delayed Neurological Deficit and Cerebral InfarctionMatthew J Kole, Aaron P Wessell, Beatrice Ugiliweneza, et al.
British Journal of Haematology|April 12, 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinibJeffrey A Jones, Peter Hillmen, Steven Coutre, et al.
Environmental Toxicology and Chemistry|September 18, 2007
Intra- and interlaboratory variability in acute toxicity tests with glochidia and juveniles of freshwater mussels (Unionidae)Ning Wang, Tom Augspurger, M Chris Barnhart, et al.
The Journal of Biological Chemistry|November 24, 1999
Engineering a glucose-responsive human insulin-secreting cell line from islets of Langerhans isolated from a patient with persistent hyperinsulinemic hypoglycemia of infancyW M MacFarlane, J C Chapman, R M Shepherd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSteven E Coutré, Richard R Furman, Ian W Flinn, et al.
Pageof 102